AVCN Avicanna Inc.

0.0594USD0.0850 CAD · TSX-2.86%Mkt Cap: 7.98M USDP/E: —

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmace…

Institutional holders1 on file

Key Statistics

Company
Market Cap7.98M USD
Enterprise Value14.54M USD
Revenue (TTM)17.70M USD
Gross Profit9.45M USD
Net Income (TTM)-1.99M USD
Revenue/Share0.15 USD
Last Price0.0594 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees112
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA05368K1003
Valuation
P/E (Trailing)—
P/E (Forward)-1.42
PEG—
EV/EBITDA-6.69
EV/Revenue0.82
P/S0.45
P/B3.54
EPS (TTM)-0.02 USD
EPS (Forward)-0.04 USD
52W Range
0.05593% of range0.1957
52W High0.1957 USD
52W Low0.0559 USD
Profitability
Gross Margin53.06%
Oper. Margin-14.02%
EBITDA Margin-12.28%
Profit Margin-11.16%
ROE-100.02%
ROA-13.39%
ROIC-19.79%
ROCE-23.06%
Growth
Revenue Growth-8.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-825.74K USD
CapEx (TTM)178.87K USD
FCF Margin-5.34%
FCF Yield-11.83%
Net Debt-21.57K USD
Net Debt/EBITDA0.01
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio0.97
Quick Ratio0.45
Book Value/Sh0.02 USD
Cash/Share0.0007 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.134.38M
Float117.65M
Insiders21.29%
Institutions0.00%
Short Interest
Short Ratio0.3d
Short % Out.0.01%
Shares Short15.21K
Short (prev mo.)30.34K
Technical
SMA 500.0726 (-18.2%)
SMA 2000.0931 (-36.2%)
Beta0.35
S&P 52W Chg12.00%
Avg Vol (30d)219.16K
Avg Vol (10d)542.75K
Technical Indicators
RSI (14)38.5
MACD-0.0051
MACD Signal-0.0039
MACD Hist.-0.0013
BB Upper0.0803 USD
BB Middle0.0688 USD
BB Lower0.0572 USD
BB Width33.68%
ATR (14)0.0046 USD
Vol Ratio (20d)0.22x

About Avicanna (TSE: AVCN)

›

Avicanna (TSE: AVCN) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 112 employees.

The shares were at 0.0850 CAD on 19 November 2026, down 67.3% over 52 weeks. Its 52-week range is 0.0800 CAD to 0.2800 CAD: the price is 69.6% below the high and 6.3% above the low.

Its market capitalisation is 11.42M CAD.

Avicanna reports return on equity of -100.0%, an operating margin of -14.0% and revenue down 8.4% year over year.

It holds more cash than debt, a net cash position of 30.85K CAD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 31 March 2027.